Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of DTcP Vaccine in Healthy Children
NCT04099303Phase 1Completed
- Sponsor
- CanSino Biologics Inc.
- Start
- Apr 2020
- Primary completion
- Oct 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of diphtheria + tetanus + acellular pertussis (3-component) in diphtheria, Tetanus and pertussis, sponsored by CanSino Biologics Inc. Primary endpoints: Safety items of adverse reactions, Occurrence of Serious Adverse Events (SAE) and 1 more. Started Apr 2020; status: completed.
02
Drugs
diphtheria + tetanus + acellular pertussis (3-component)
03
Conditions
diphtheriaTetanuspertussis
Beyond the preview
Go deeper on NCT04099303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04099303.